This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Deborah S. Smith, PhD; William J. Catalona, MD; Jonathan D. Herschman, MD

JAMA. 1996;276(16):1309-1315.

Abstract
Objective.
—To determine for the first 4 years of serial prostate-specific antigen (PSA)-based screening trends in compliance, prevalence of abnormal screening test results, cancer detection rates, and stage and grade of cancers detected.

Design.
—A community-based study of serial screening for prostate cancer with serum PSA measurements.

Setting.
—University medical center.

Subjects.
—A total of 10 248 male volunteers at least 50 years old who were screened at 6-month intervals for a minimum of 48 months.

Main Outcome Measures.
—The proportion of men who returned for serial screening, the proportion with elevated PSA levels, the proportion with newly elevated PSA levels, prostate cancer detection rates, and the distribution of tumor stages and grades at diagnosis.

Results.
—At 48 months, 79% of volunteers returned for screening. During this interval there was a decrease in the proportion of volunteers with serum PSA levels higher than 4.0 ng/mL (from 10% to 6%-7%), in cancer detection rates (from 3% to <1%), and in the proportion with clinically advanced cancer (from 6% to 2%). In men who underwent surgery, the proportion with high-grade cancer decreased (from 11% to 6%). and the proportion with pathologically advanced cancer was proportionately reduced but not significantly reduced (from 33% to 27%).

Conclustons.
—With serial PSA-based screening, the proportion of men with abnormal test results decreased, and the prostate cancer detection rate decreased to near the reported population-based incidence rate. There was also a shift to detection of cancers at an earlier clinical stage and detection of lower-grade cancers. If PSA screening is ultimately shown to be beneficial, then appropriate cost-benefit analyses will be required to determine how the shifts in cancer detection rate and cancer stage will affect the economics of serial PSA-based screening.

Author Affiliations
From the Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Mo.

Footnotes
Reprints: Deborah S. Smith, PhD, Division of Urologic Surgery, Washington University School of Medicine, 4960 Children's PI, St Louis, MO 63110.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer
Gupta et al.
Clin. Cancer Res. 2008;14:7385-7390.
ABSTRACT | FULL TEXT  

Assessing risk: does this patient have prostate cancer?
Carter
JNCI J Natl Cancer Inst 2006;98:506-507.
FULL TEXT  

Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal
Welch et al.
JNCI J Natl Cancer Inst 2005;97:1132-1137.
ABSTRACT | FULL TEXT  

Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice
Soletormos et al.
Clin. Chem. 2005;51:1342-1351.
ABSTRACT | FULL TEXT  

Prostate Cancers in Men with Low PSA Levels -- Must We Find Them?
Carter
NEJM 2004;350:2292-2294.
FULL TEXT  

Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy
Shariat et al.
JCO 2004;22:1655-1663.
ABSTRACT | FULL TEXT  

Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial
Makinen et al.
Clin. Cancer Res. 2004;10:2231-2236.
ABSTRACT | FULL TEXT  

Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris and Lohr
ANN INTERN MED 2002;137:917-929.
ABSTRACT | FULL TEXT  

Novel Artificial Neural Network for Early Detection of Prostate Cancer
Djavan et al.
JCO 2002;20:921-929.
ABSTRACT | FULL TEXT  

Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 With Prostate Cancer Invasion, Progression, and Metastasis
Shariat et al.
JCO 2002;20:833-841.
ABSTRACT | FULL TEXT  

Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGF-{beta}1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy
Shariat et al.
JCO 2001;19:2856-2864.
ABSTRACT | FULL TEXT  

Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
Catalona et al.
JAMA 1998;279:1542-1547.
ABSTRACT | FULL TEXT  

Detection of Early Prostate Cancer: Serendipitous or Systematic?
Iczkowski et al.
JAMA 1998;279:1439-1441.
FULL TEXT  

Urology
Albertsen
JAMA 1997;277:1904-1905.
 

Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination: Enhancement of Specificity With Free PSA Measurements
Catalona et al.
JAMA 1997;277:1452-1455.
ABSTRACT  

Recommended Prostate-Specific Antigen Testing Intervals for the Detection of Curable Prostate Cancer
Carter et al.
JAMA 1997;277:1456-1460.
ABSTRACT  

Prostate Cancer Screening
Atkins
JAMA 1997;277:299-300.
ABSTRACT